Private: Gallery Post #1

12

Apr2018
Released yesterday, the Government of Saskatchewan’s 2018-19 budget earmarked a record $5.36B for provincial health initiatives, including $600,000 to provide HIV medications at no cost for eligible Saskatchewan Health beneficiaries. This announcement eliminates cost-sharing deductibles/co-payments that were previously included as part of the province’s coverage of HIV medications. This ... Read More

12

Apr2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2018: 40 negotiations are currently underway with 4 new files added since the last update of February 28, 2018: Darzalex (daratumumab): Used to treat multiple myeloma Fiasp (insulin aspart): Used to ... Read More

05

Apr2018
On April 4, 2018, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the evaluation process. Pre-NOC Evaluations Manufacturers can submit an application for registration to INESSS for a new innovative drug product, a new biosimilar drug product, a new product ... Read More

29

Mar2018
Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018 In January 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) announced a five-year agreement that will reduce drug prices for all Canadians who use prescription generic drugs, participating public drug plans, and employee ... Read More

21

Mar2018
Since launching a pilot project to expand clinician participation in the pan-Canadian Oncology Drug Review (pCODR) process in February 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) has received input from clinicians, the pCODR Expert Review Committee and the Provincial Advisory Group on ways to enhance ... Read More

09

Mar2018
On March 8, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 134). CADTH Common Drug Review Submissions May Be Filed up to 180 Days before Market Authorization In support of the Health Canada’s Regulatory Review of Drugs and Devices (R2D2) initiative and ... Read More

08

Mar2018
The PMPRB has released its March 2018 NEWSletter. This is the first NEWSletter posted by the PMPRB in several months. While the details of the framework to modernize the PMPRB Guidelines remain to be worked out through consultation, its basic structure can be described as a risk-based approach to pricing review ... Read More

27

Feb2018
This afternoon Federal Finance Minister Bill Morneau unveiled his government’s third budget, focussing on a strong middle class, gender equality, indigenous reconciliation, and – as leaked yesterday upon the resignation of Ontario Health Minister Eric Hoskins – a new Advisory Council on the Implementation of National Pharmacare. According to Budget 2018, ... Read More

23

Feb2018
On February 21, 2018, the Gazette officielle du Québec announced that draft regulations, relating to the implementation of fees for manufacturers submitting a scientific evaluation to the Institut national d’excellence en santé et en services sociaux (INESSS), have been submitted to the government of Québec for approval. The fees will vary ... Read More

14

Feb2018
On February 13, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 133). Revisions to CADTH’s Biosimilar Review Process In August 2017, CADTH issued a consultation to seek input on how biosimilar reviews could be enhanced in Canada. Based on the ... Read More